1465908-73-9
Chemical Structure
Tasipimidine sulfate
- CAS No.: 1465908-73-9
- Formula:C13H18N2O6S
- Molecular Weight:330.36
IUPAC Name: 2-(5-methoxyisochroman-1-yl)-4,5-dihydro-1H-imidazole sulfate
InChIKey: HZWPSPYSMWTZTG-UHFFFAOYSA-N
SMILES: O=S(O)(O)=O.COC1=CC=CC2=C1CCOC2C3=NCCN3
Biological Activity: Tasipimidine sulfate is an orally active and selective α2A-adrenoceptor agonist with a pEC50 of 7.57 for human α2A-adrenoceptors and an EC50 of 5.7 nM for rat α2-adrenoceptor. Tasipimidine sulfate can be utilized in research related to situational anxiety and fear[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tasipimidine sulfate | 99.32% | Tasipimidine sulfate is an orally active and selective α2A-adrenoceptor agonist with a pEC50 of 7.57 for human α2A-adrenoceptors and an EC50 of 5.7 nM for rat α2-adrenoceptor. Tasipimidine sulfate can be utilized in research related to situational anxiety and fear. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tasipimidine sulfate (Standard) | ≥98% | Tasipimidine sulfate (Standard) is the analytical standard of Tasipimidine (sulfate) (HY-109075A). This product is intended for research and analytical applications. Tasipimidine sulfate is an orally active and selective α2A-adrenoceptor agonist with a pEC50 of 7.57 for human α2A-adrenoceptors and an EC50 of 5.7 nM for rat α2-adrenoceptor. Tasipimidine sulfate can be utilized in research related to situational anxiety and fear. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Lehtimäki J, et al. Tasipimidine-the pharmacological profile of a novel orally active selective α2A-adrenoceptor agonist. Eur J Pharmacol. 2022 May 15;923:174949. [Content Brief]
- [2]. Korpivaara M, et al. Tasipimidine, a novel orally administered alpha-2 adrenoceptor agonist, alleviates canine acute anxiety associated with owner departure—A pilot study. Journal of Veterinary Behavior, 2022, 58: 54-61.